AU2017376445B2 - Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use - Google Patents

Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use Download PDF

Info

Publication number
AU2017376445B2
AU2017376445B2 AU2017376445A AU2017376445A AU2017376445B2 AU 2017376445 B2 AU2017376445 B2 AU 2017376445B2 AU 2017376445 A AU2017376445 A AU 2017376445A AU 2017376445 A AU2017376445 A AU 2017376445A AU 2017376445 B2 AU2017376445 B2 AU 2017376445B2
Authority
AU
Australia
Prior art keywords
fluoro
thiazin
fluorophenyl
fluorovinyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017376445A
Other languages
English (en)
Other versions
AU2017376445A1 (en
Inventor
Jennifer R. Allen
Matthew P. Bourbeau
Ning Chen
Qingyian Liu
Liping H. Pettus
Aaron C. Siegmund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2017376445A1 publication Critical patent/AU2017376445A1/en
Application granted granted Critical
Publication of AU2017376445B2 publication Critical patent/AU2017376445B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU2017376445A 2016-12-15 2017-12-13 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use Active AU2017376445B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662434719P 2016-12-15 2016-12-15
US62/434,719 2016-12-15
US201762570429P 2017-10-10 2017-10-10
US62/570,429 2017-10-10
PCT/US2017/066180 WO2018112084A1 (en) 2016-12-15 2017-12-13 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
AU2017376445A1 AU2017376445A1 (en) 2019-07-04
AU2017376445B2 true AU2017376445B2 (en) 2021-09-30

Family

ID=60888746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017376445A Active AU2017376445B2 (en) 2016-12-15 2017-12-13 Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use

Country Status (9)

Country Link
US (1) US11548903B2 (enExample)
EP (1) EP3555106B1 (enExample)
JP (1) JP7148518B2 (enExample)
AU (1) AU2017376445B2 (enExample)
CA (1) CA3047285A1 (enExample)
ES (1) ES2910367T3 (enExample)
MA (1) MA54101A (enExample)
MX (1) MX394391B (enExample)
WO (1) WO2018112084A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011071135A1 (ja) † 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
EP3555085B1 (en) 2016-12-15 2020-12-02 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
CA3047286A1 (en) * 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555106B1 (en) 2016-12-15 2022-03-09 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093999A1 (en) * 2008-09-30 2010-04-15 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
WO2011009898A1 (en) * 2009-07-22 2011-01-27 Eisai R&D Management Co., Ltd Fused aminodihydro-oxazine derivatives
WO2012098213A1 (en) * 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives useful as bace inhibitors
WO2014143579A1 (en) * 2013-03-12 2014-09-18 Eli Lilly And Company Tetrahydropyrrolothiazine compounds
WO2017024180A1 (en) * 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
KR100768381B1 (ko) 1998-09-24 2007-10-18 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
ES2476027T3 (es) 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
HRP20151030T1 (hr) 2008-01-18 2015-11-06 Eisai R&D Management Co., Ltd. Kondenzirani derivat aminodihidrotiazina
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2500344A4 (en) 2009-11-13 2013-05-01 Shionogi & Co AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
JPWO2011070781A1 (ja) 2009-12-09 2013-04-22 塩野義製薬株式会社 置換アミノチアジン誘導体
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
CA2824097A1 (en) 2011-01-12 2012-07-19 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
MA34898B1 (fr) 2011-01-13 2014-02-01 Novartis Ag Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2012139425A1 (en) 2011-04-13 2012-10-18 Schering Corporation 5-substituted iminothiazines and their mono-and dioxides as bace inhibitors,compositions,and their use
CN103649082A (zh) 2011-04-26 2014-03-19 盐野义制药株式会社 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂
EP2517898A1 (de) 2011-04-29 2012-10-31 Lanxess Deutschland GmbH Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013142613A1 (en) 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
WO2013182638A1 (en) 2012-06-08 2013-12-12 H. Lundbeck A/S 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9328124B2 (en) 2012-10-26 2016-05-03 Eli Lilly And Company BACE inhibitors
US9447085B2 (en) 2012-12-14 2016-09-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014098831A1 (en) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
EP2934534B1 (en) 2012-12-21 2017-12-13 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
SG11201708027XA (en) 2015-04-21 2017-11-29 Allgenesis Biotherapeutics Inc Compounds and their use as bace1 inhibitors
CA3047286A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555085B1 (en) 2016-12-15 2020-12-02 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
EP3555106B1 (en) 2016-12-15 2022-03-09 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093999A1 (en) * 2008-09-30 2010-04-15 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
WO2011009898A1 (en) * 2009-07-22 2011-01-27 Eisai R&D Management Co., Ltd Fused aminodihydro-oxazine derivatives
WO2012098213A1 (en) * 2011-01-21 2012-07-26 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives useful as bace inhibitors
WO2014143579A1 (en) * 2013-03-12 2014-09-18 Eli Lilly And Company Tetrahydropyrrolothiazine compounds
WO2017024180A1 (en) * 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Also Published As

Publication number Publication date
ES2910367T3 (es) 2022-05-12
WO2018112084A1 (en) 2018-06-21
AU2017376445A1 (en) 2019-07-04
EP3555106A1 (en) 2019-10-23
MX394391B (es) 2025-03-24
CA3047285A1 (en) 2018-06-21
JP7148518B2 (ja) 2022-10-05
EP3555106B1 (en) 2022-03-09
US11548903B2 (en) 2023-01-10
MA54101A (fr) 2021-10-27
US20200199153A1 (en) 2020-06-25
JP2020503294A (ja) 2020-01-30
MX2019007100A (es) 2019-12-16

Similar Documents

Publication Publication Date Title
AU2017376445B2 (en) Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555080B1 (en) Oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555086B1 (en) 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
AU2017376444B2 (en) Thiazine derivatives as beta-secretase inhibitors and methods of use
AU2017378316B2 (en) Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
WO2024033845A1 (en) Heterocyclic compound
CA3047287C (en) Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)